Under Innovate UK’s Sustainable Medicines Manufacturing Innovation Programme (SMMIP) Labman will help deliver the advanced automation and smart bioprocessing infrastructure needed to accelerate the “Sustainable Future Factory” vision.
At the centre of Labman’s contribution is its rapidly growing Bioprocessing business unit, bringing deep expertise in GMP-compliant automation, smart QC workflows, and scalable robotic systems that bridge the gap between early-stage R&D and industrial manufacturing.
Labman’s modular, automated platforms will support the initiative’s mission to:
- Boost the UK’s biomanufacturing capacity through flexible, automation-ready facilities
- Accelerate translation from scientific discovery to real-world products
- Enhance quality and reproducibility through intelligent QC automation
- Enable compliance-ready scale-up, helping innovators move more quickly and safely toward regulated production
Labman’s long-standing expertise in GMP automation, electronic batch record integration, in-line QC, and robotic bioprocessing workflows uniquely positions the company to support this national programme.
Building on the momentum of its recently announced AI-driven bioreactor project, which showcases how intelligent automation can transform early-stage bioprocess development, Labman is enabling consistent, audit-ready manufacturing from day one to help de-risk scale-up and ensure that the UK’s new wave of biotech innovators can move quickly into regulated environments. This initiative marks a significant step toward creating a resilient, globally competitive engineering biology and medicines manufacturing ecosystem, and Labman is proud to be shaping that future.
About Labman
Labman designs and builds world-leading automated laboratory and bioprocessing systems. From modular labs to fully integrated GMP-compliant bioprocessing platforms, Labman empowers scientists, engineers, and manufacturers to scale breakthrough ideas into real-world impact.